Dianthus Therapeutics (NASDAQ:DNTH) Stock: Insider Ryan Savitz Sells 100,713 Shares

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 100,713 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $90.54, for a total transaction of $9,118,555.02. Following the transaction, the executive vice president directly owned 29,276 shares of the company’s stock, valued at $2,650,649.04. This represents a 77.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Ryan Savitz also recently made the following trade(s):

• On Wednesday, November 11th, Ryan Savitz sold 3,044 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.03, for a total transaction of $274,051.32.
• On Thursday, November 12th, Ryan Savitz sold 17,724 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.56, for a total transaction of $1,605,085.44.
• On Tuesday, November 10th, Ryan Savitz sold 2,561 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.14, for a total transaction of $230,848.54.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock traded up $3.18 during mid-day trading on Thursday, reaching $92.48. The company’s stock had a trading volume of 921,016 shares, compared to its average volume of 931,449. Dianthus Therapeutics, Inc. has a 12 month low of $34.29 and a 12 month high of $117.88. The business’s 50 day simple moving average is $89.05 and its 200 day simple moving average is $86.15. The company has a market capitalization of $5.21 billion, a price-to-earnings ratio of -23.18 and a beta of 1.47.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.13. Dianthus Therapeutics had a negative net margin of 7,436.50% and a negative return on equity of 19.68%. The firm had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $0.46 million. As a group, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -3.55 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DNTH. ABS Investment Management LLC bought a new stake in Dianthus Therapeutics in the second quarter valued at approximately $194,960,000. EFG International AG bought a new stake in Dianthus Therapeutics in the 2nd quarter valued at $49,000. GAMMA Investing LLC raised its stake in Dianthus Therapeutics by 83.6% in the 3rd quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock valued at $49,000 after acquiring an additional 254 shares during the period. Fifth Third Bancorp lifted its holdings in Dianthus Therapeutics by 23.6% during the 3rd quarter. Fifth Third Bancorp now owns 676 shares of the company’s stock valued at $60,000 after purchasing an additional 129 shares during the last quarter. Finally, Global Retirement Partners LLC acquired a new stake in Dianthus Therapeutics during the 2nd quarter valued at $93,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DNTH has been the topic of several analyst reports. Roth Capital initiated coverage on Dianthus Therapeutics in a report on Tuesday, October 27th. They set a “buy” rating and a $113.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Wedbush boosted their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. HC Wainwright reiterated a “buy” rating and set a $158.00 price objective on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Finally, Citigroup assumed coverage on Dianthus Therapeutics in a report on Friday, September 4th. They issued a “buy” rating and a $156.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $128.77.

About Dianthus Therapeutics

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.